POU2F1 is usually overexpressed in NHL, which may lead to higher susceptibility to therapies as irinotecan, paclitaxel, and mutations on POU2F1 may lead to tumor resistance against chemotherapies (Gupta et al., 2012). This evidence concerns the gene POU2F1 and non-Hodgkin lymphoma.